The human CYP2C is a subfamily of P450 enzymes that metabolize approximately 20% of clinically used drugs (Goldstein 2001). The four members of the subfamily are: CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 is an enzyme of major importance in human drug metabolism. Substrates for CYP2C9 include phenytoin (Banpai et al. 1996), S-warfarin (Rettie et al. 1992), acenocoumarol (Verstuyft et al. 2003a), losartan (Stearns et al. 1995), tolbutamide (Miners & Birkett 1996), glipizide (Kidd et al. 1999), fluvastatin (Kirchheiner et al. 2003) and some NSAIDs (Miners & Birkett 1998). Six different human CYP2C9 cDNA sequences have been reported to make the enzyme polymorphic (Stubbins et al. 1996). Since the wildtype CYP2C9*1 and the single nucleotide polymorphisms CYP2C9*2 and CYP2C9*3 were discovered first, they have undergone more thorough investigation showing that the allelic variants CYP2C9*2 and CYP2C9*3 encode enzymes with decreased substrate turnover (Craig et al. 2002; Kirchheiner et al. 2002; Shon et al. 2002). The CYP2C9*2 allele, which is derived from a C430→T single nucleotide polymorphism in exon 3, encodes the Arg144→Cys substitution, whereas a A1075→C single nucleotide polymorphism in exon 7 results in the substitution Ile359→Leu for CYP2C9*3 (Stubbins et al. 1996). The allele frequencies of CYP2C9*1, CYP2C9*2 and CYP2C9*3 and the genotype frequencies of CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 for a Nordic population in Denmark were determined. Two hundred seventy-six healthy Nordic (mainly Danish) volunteers of Caucasian origin were enrolled in the study. The 154 males and 122 females aged 19–42 were primarily students at the University of Southern Denmark. The protocol was approved by The Scientific Ethical Committee for Vejle and Funen Counties. A written informed consent to participate in the study was obtained from the volunteers. Two×10 ml venous blood was obtained with EDTA as anticoagulant from each volunteer. The DNA from peripheral leukocytes was isolated by PUREGENETM genomic DNA purification kit by Gentra Systems, Minnesota 55441, USA, according to the guidelines of the manufacturer. Genotyping of variants was performed by allelic discrimination based on fluorescent PCR (Verstuyft et al. 2003b). Table 1 shows the genotype and allele frequencies of CYP2C9 for the population. Table 2 shows the comparison of allele and genotype frequencies of CYP2C9 in populations from different European studies. The CYP2C9 genetic polymorphism has been well studied in Caucasians and the frequencies of CYP2C9*1,CYP2C9*2 and CYP2C9*3 alleles found in the Nordic population were similar to those found in other European populations. The allelic frequencies were 83% (79–86%) for CYP2C9*1, 12% (9.5–15%) for CYP2C9*2 and 5.3% (3.5–7.5%) for CYP2C9*3. The expected frequency of CYP2C9*3/*3 in the Nordic population according to the Hardy-Weinberg law is (5.3%)2=0.28%. The expected number of CYP2C9*3/*3 in the Nordic population of 276 individuals is therefore 0.8. Not surprisingly, no CYP2C9*3/*3 was found in the population. The CYP2C9 polymorphism is of clinical relevance for drugs which are metabolized almost exclusively by the enzyme that has a small therapeutic index and for which clinical dose titration is not feasible. Warfarin is a very likely candidate, and clinical studies (Scordo et al. 2002) have shown that the CYP2C9 genotype is a major determinant of maintenance dose and metabolic clearance of S-warfarin. However, even within the 6 genotypes in table 1 and 2 Scordo et al. (2002) reported a considerable interindividual variability. Thus further studies are warranted before CYP2C9 genotyping can be recommended previous to warfarin treatment.